These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12683404)

  • 1. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
    Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
    J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates.
    Davis D; Donners H; Willems B; Ntemgwa M; Vermoesen T; van der Groen G; Janssens W
    J Med Virol; 2006 Jul; 78(7):864-76. PubMed ID: 16721864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
    Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells.
    Beirnaert E; De Zutter S; Janssens W; van der Groen G
    Virology; 2001 Mar; 281(2):305-14. PubMed ID: 11277702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
    Spenlehauer C; Kirn A; Aubertin AM; Moog C
    J Virol; 2001 Mar; 75(5):2235-45. PubMed ID: 11160727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization.
    Fortin JF; Cantin R; Bergeron MG; Tremblay MJ
    Virology; 2000 Mar; 268(2):493-503. PubMed ID: 10704357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates.
    Darden JM; Polonis VR; deSouza MS; Chantakulkij S; Brown AE; Birx DL; Pattanapanyasat K
    Cytometry; 2000 Jun; 40(2):141-50. PubMed ID: 10805934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to infection by HIV-1 of peripheral blood mononuclear cells from HIV-1-infected patients is probably mediated by neutralizing antibodies.
    Tremblay M; Numazaki K; Li XG; Gornitsky M; Hiscott J; Wainberg MA
    J Immunol; 1990 Nov; 145(9):2896-901. PubMed ID: 1698866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
    Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
    Braibant M; Gong EY; Plantier JC; Moreau T; Alessandri E; Simon F; Barin F
    AIDS; 2013 May; 27(8):1239-44. PubMed ID: 23343910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
    Louder MK; Sambor A; Chertova E; Hunte T; Barrett S; Ojong F; Sanders-Buell E; Zolla-Pazner S; McCutchan FE; Roser JD; Gabuzda D; Lifson JD; Mascola JR
    Virology; 2005 Sep; 339(2):226-38. PubMed ID: 16005039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
    Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
    Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.